DrugPatentWatch Database Preview
TAKEDA Company Profile
What is the competitive landscape for TAKEDA, and what generic alternatives to TAKEDA drugs are available?
TAKEDA has twenty-one approved drugs.
There are eighty-eight US patents protecting TAKEDA drugs.
There are one thousand one hundred and seven patent family members on TAKEDA drugs in fifty-eight countries and ninety-eight supplementary protection certificates in fifteen countries.
Summary for TAKEDA
| International Patents: | 1107 |
| US Patents: | 88 |
| Tradenames: | 22 |
| Ingredients: | 16 |
| NDAs: | 21 |
| Patent Litigation for TAKEDA: | See patent lawsuits for TAKEDA |
| PTAB Cases with TAKEDA as patent owner: | See PTAB cases with TAKEDA as patent owner |
Drugs and US Patents for TAKEDA
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Takeda Pharms Usa | OMONTYS PRESERVATIVE FREE | peginesatide acetate | SOLUTION;INTRAVENOUS, SUBCUTANEOUS | 202799-004 | Mar 27, 2012 | DISCN | No | No | 7,919,118 | ➤ Try a Free Trial | Y | Y | ➤ Try a Free Trial | ||
| Takeda Pharms Usa | OMONTYS | peginesatide acetate | SOLUTION;INTRAVENOUS, SUBCUTANEOUS | 202799-008 | Mar 27, 2012 | DISCN | No | No | 7,084,245 | ➤ Try a Free Trial | Y | Y | ➤ Try a Free Trial | ||
| Takeda Pharms Usa | DEXILANT | dexlansoprazole | CAPSULE, DELAYED RELEASE;ORAL | 022287-001 | Jan 30, 2009 | RX | Yes | No | 7,790,755*PED | ➤ Try a Free Trial | Y | ➤ Try a Free Trial | |||
| Takeda Pharms Usa | OSENI | alogliptin benzoate; pioglitazone hydrochloride | TABLET;ORAL | 022426-001 | Jan 25, 2013 | RX | Yes | No | 7,078,381 | ➤ Try a Free Trial | ➤ Try a Free Trial | ||||
| Takeda Pharms Usa | TRINTELLIX | vortioxetine hydrobromide | TABLET;ORAL | 204447-001 | Sep 30, 2013 | RX | Yes | No | 8,476,279 | ➤ Try a Free Trial | Y | ➤ Try a Free Trial | |||
| Takeda Pharms Usa | DEXILANT | dexlansoprazole | CAPSULE, DELAYED RELEASE;ORAL | 022287-002 | Jan 30, 2009 | AB | RX | Yes | Yes | 6,462,058*PED | ➤ Try a Free Trial | Y | ➤ Try a Free Trial | ||
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
Expired US Patents for TAKEDA
Paragraph IV (Patent) Challenges for TAKEDA drugs
| Drugname | Dosage | Strength | Tradename | Submissiondate |
|---|---|---|---|---|
| ➤ Subscribe | Delayed-release Pellets/Capsul | 15 mg and 30 mg | ➤ Subscribe | 2005-12-05 |
| ➤ Subscribe | Capsule | 60 mg | ➤ Subscribe | 2010-08-25 |
| ➤ Subscribe | Extended-release Tablets | 15 mg/1000 mg and 30 mg/1000 mg | ➤ Subscribe | 2011-09-23 |
| ➤ Subscribe | Tablets | 0.6 mg | ➤ Subscribe | 2011-12-23 |
| ➤ Subscribe | Tablets | 12.5 mg/500 mg and 12.5 mg/1000 mg | ➤ Subscribe | 2017-01-25 |
| ➤ Subscribe | Tablets | 8 mg | ➤ Subscribe | 2009-07-22 |
| ➤ Subscribe | Tablets | 40 mg and 80 mg | ➤ Subscribe | 2013-02-13 |
| ➤ Subscribe | Delayed-release Orally Disinte | 15 mg and 30 mg | ➤ Subscribe | 2006-12-27 |
| ➤ Subscribe | Delayed-release Capsule | 30 mg | ➤ Subscribe | 2010-11-30 |
| ➤ Subscribe | Tablets | 15 mg/500 mg and 15 mg/850 mg | ➤ Subscribe | 2008-03-06 |
| ➤ Subscribe | Tablets | 30 mg/2 mg and 30 mg/4 mg | ➤ Subscribe | 2009-12-22 |
| ➤ Subscribe | Tablets | 6.25 mg, 12.5 mg and 25 mg | ➤ Subscribe | 2017-01-25 |
| ➤ Subscribe | Tablets | 5 mg, 10 mg, 15 mgand 20 mg | ➤ Subscribe | 2017-10-02 |
International Patents for TAKEDA Drugs
| Country | Document Number | Estimated Expiration |
|---|---|---|
| Cyprus | 1107924 | ➤ Try a Free Trial |
| Slovakia | 115098 | ➤ Try a Free Trial |
| Japan | 5563735 | ➤ Try a Free Trial |
| Spain | 2288807 | ➤ Try a Free Trial |
| European Patent Office | 1199304 | ➤ Try a Free Trial |
| Australia | 2008323390 | ➤ Try a Free Trial |
| Country | Document Number | Estimated Expiration |
Supplementary Protection Certificates for TAKEDA Drugs
| Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|
| 374 | Luxembourg | ➤ Try a Free Trial | PRODUCT NAME: ALOGLIPTIN SOUS TOUTES SES FORMES TELLES QUE PROTEGEES PAR LE BREVET DE BASE. FIRST REGISTRATION: 20130923 |
| 2014011 | Lithuania | ➤ Try a Free Trial | PRODUCT NAME: ALOGLIPTINUM; REGISTRATION NO/DATE: EU/1/13/844 20130919 |
| C015/2010 | Ireland | ➤ Try a Free Trial | SPC015/2010: 20101001, EXPIRES: 20230420 |
| 00357 | Netherlands | ➤ Try a Free Trial | PRODUCT NAME: SITAGLIPTINE, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVA ARDBAAR ZOUT, IN HET BIJZONDER HET MONOFOSFAAT, EN METFORMINE DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT, IN HET BIJZONDER HET HYDROCHLORIDE; REGISTRATION NO/DATE: EU/1/08/455/001-014 20080716 |
| C0022 | France | ➤ Try a Free Trial | PRODUCT NAME: FEBUXOSTAT; REGISTRATION NO/DATE: EU/1/08/447/001-004 20080421 |
| 2014026 | Lithuania | ➤ Try a Free Trial | PRODUCT NAME: DAPAGLIFOZINUM + METFORMINUM; REGISTRATION NO/DATE: EU/1/13/900 20140116 |
| Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
